27 May 2024 • A major study published in the New England Journal of Medicine has found that semaglutide significantly reduces the risk of kidney failure and cardiovascular death in patients with type 2 diabetes and chronic kidney disease.

The study, which included 3533 participants, found that those treated with semaglutide had a 24% lower risk of severe kidney events and death from cardiovascular causes compared to placebo.

Additionally, semaglutide slowed kidney function decline and reduced the risk of major cardiovascular events by 18% and overall mortality by 20%.

The magnitude of the benefits observed in this trial provides confidence that the use of semaglutide in patients with type 2 diabetes and chronic kidney disease will reduce the risk of kidney failure and slow the decline in the eGFR, as well as reduce the risk of cardiovascular events and death.

Source: NEJM | Read full story